Biotech Values

[AlpineBV_Miller]

Miller’s main point is that Provenge will have a lower gross margin than a typical biopharmaceutical. We won’t know how much lower until we know the price, but I think it’s clear that Provenge’s gross margin will be on the low side at any conceivable pricing level.

Dew's right, but I bet we'll be in the right range around 70%. I think we've got better than an average guess at what the company plans to charge after umpteen years of covering the story.